Search results
Results from the WOW.Com Content Network
Proparacaine 0.5% is marketed as Poencaina by Poen Laboratories. [5] References This page was last edited on 14 January 2025, at 03:34 (UTC). Text is available ...
When used excessively, oxybuprocaine like any other topical anesthetic used in the eye and on mucous membranes (like for example tetracaine, proxymetacaine and proparacaine) can cause irritation, hypersensitivity, anaphylaxis, irreversible corneal damage and even complete destruction of the cornea.
Figure 1.0 - Basic anatomical features of the human eye. Ophthalmic drug administration is the administration of a drug to the eyes, most typically as an eye drop formulation. Topical formulations are used to combat a multitude of diseased states of the eye. These states may include bacterial infections, eye injury, glaucoma, and dry eye. [1]
Researchers have recently developed a new drug that will ultimately shrink down and dissolve cataracts -- the leading cause of human blindness that affects tens of millions of people worldwide. ...
Visine (/ ˌ v aɪ ˈ z iː n /), also known as Vispring, is a brand of eye drops produced by Kenvue. [1] Visine was first introduced in 1958 and was acquired by Pfizer in 1999. [2] [3] In 2006, Johnson & Johnson acquired Visine, along with Pfizer's entire consumer healthcare portfolio. [4]
Lanosterol is under research for its potential as a therapeutic additive in eye drops to inhibit the aggregation of crystallin proteins and dissolve cataracts. [ 3 ] [ 4 ] However, supplemental lanosterol in eye drops appears to have limited solubility and poor bioavailability in the eye, and has not proved effective for inhibiting cataracts ...
On hourly treatment with the eye drops for a week, blood serum concentrations peaked at 150 pg/ml on average, with many patients remaining below the detection threshold of 80 pg/ml. The elimination half-life from the circulation is estimated at one to two hours; the substance is mainly (over 80%) excreted via the faeces.
Glanatec, the trade name of the approved formulation, takes the form of an eye drop solution of 0.4% ripasudil, equivalent to 4 g of ripasudil per 1000 mL of solution. The solution is developed, marketed, and distributed by Kowa Pharmaceuticals, but the compound itself was discovered by D. Western Therapeutics Institute, [ 2 ] a company who ...